Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from IO Biotech ( (IOBT) ).
On June 24, 2025, IO Biotech issued a Tranche B warrant to the European Investment Bank to purchase over 4 million shares of its common stock, following the satisfaction of conditions to draw €12.5 million from a previously established finance contract. The company plans to draw down the Tranche B loan around July 4, 2025, marking a significant step in its financing strategy.
The most recent analyst rating on (IOBT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on IO Biotech stock, see the IOBT Stock Forecast page.
Spark’s Take on IOBT Stock
According to Spark, TipRanks’ AI Analyst, IOBT is a Neutral.
IO Biotech faces significant challenges due to its financial instability and lack of revenue. However, the progress in clinical trials and secured financing improve its future prospects, though it remains speculative. The technical analysis suggests neutral momentum, and the valuation highlights typical risks associated with biotech stocks awaiting commercialization.
To see Spark’s full report on IOBT stock, click here.
More about IO Biotech
IO Biotech is a company involved in the biotechnology industry, focusing on developing innovative therapies. It operates as a private limited liability company in Denmark and is a wholly-owned subsidiary of IO Biotech, Inc., a Delaware corporation.
Average Trading Volume: 155,903
Technical Sentiment Signal: Buy
Current Market Cap: $99.48M
See more data about IOBT stock on TipRanks’ Stock Analysis page.